🔍

FISCHER - Fischer Medical

📊 NSE: FISCHER 🏢 Medical Equipment & Supplies 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Fischer Medical Ventures Subsidiary Acquires 75% Stake in Indonesian Medical Firm

🟢 POSITIVE ⭐ 7/10

M&A 📅 03 Mar 2026, 03:47 PM

Fischer Medical Ventures Limited's wholly owned subsidiary, FMV Global Innovations Pte Limited, has acquired a 75% stake in PT Fischer Pariko Medical Ventures. The target entity is a newly incorporated Indonesian company focused on the wholesale of medical, scientific, and precision equipment. As the entity was incorporated in October 2024, it reported nil turnover for the 2024-25 period. This acquisition marks a strategic expansion for Fischer Medical into the Southeast Asian healthcare market.

Acquisition of 75% stake in PT Fischer Pariko Medical Ventures via a 100% owned subsidiary.
Target entity is based in Indonesia and operates in the healthcare and medical equipment wholesale industry.
The acquired company is a startup incorporated on October 14, 2024, with nil revenue for FY24-25.
The move signifies an international expansion strategy into the Indonesian medical equipment market.

💡 Investors should monitor the operational progress of this new Indonesian venture as it begins generating revenue. While the acquisition is strategic, the target is a startup, so immediate financial impact will be limited.

Fischer Medical Launches India's First Helium-Free 1.5T MRI Platforms MICA and QUIN

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 09 Feb 2026, 04:48 PM

Fischer Medical Ventures Limited, through its subsidiary Time Medical India, has launched two advanced 1.5T MRI platforms, MICA and QUIN, at IRIA 2026. QUIN is distinguished as India's first helium-free 1.5T wide 70 cm bore MRI system, which eliminates helium dependency and simplifies installation. Both systems have secured CDSCO certification, allowing for immediate commercial rollout in the Indian healthcare market. These launches represent a significant technological milestone for the company in the sustainable medical imaging sector.

Launched QUIN, India's first helium-free 1.5T wide 70 cm bore MRI system.
Introduced MICA, a 1.5T 32-channel MRI with 1000-litre zero boil-off magnet technology.
Both MRI platforms have received mandatory CDSCO certification for the Indian market.
QUIN features a no-quench-pipe auto ramp unit, reducing infrastructure requirements.
Systems are available in 32 and 64-channel configurations for high-resolution imaging.

💡 The launch of India's first helium-free MRI technology positions Fischer as a leader in cost-effective medical imaging. Investors should watch for order book growth and hospital partnerships following this launch.

Fischer Medical Clarifies Single Segment Operations for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 05 Feb 2026, 01:01 PM

Fischer Medical Ventures Limited has responded to a clarification sought by the National Stock Exchange regarding its Q3 FY26 financial results. The exchange had flagged the non-submission of segment-wise details in the initial filing dated January 30, 2026. The company clarified that it operates in a single business segment, specifically Healthcare Equipment and Supplies, and therefore separate reporting is not required under accounting standards. The company further noted that this information was correctly captured in the XBRL filing utility.

NSE sought clarification regarding Regulation 33 compliance for the quarter ended December 31, 2025
Company confirms it operates exclusively in the Healthcare Equipment and Supplies segment
Clarification issued on February 4, 2026, following the initial results submission on January 30, 2026
Management maintains that segment information was duly disclosed in the XBRL Excel utility

💡 This is a routine regulatory clarification with no impact on the company's financial health. Investors should focus on the actual Q3 earnings performance rather than this compliance-related filing.

Fischer Medical Ventures Announces Resignation of Company Secretary AravindKumar V

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 30 Jan 2026, 05:20 PM

Fischer Medical Ventures Limited has announced that Mr. AravindKumar V has resigned from his role as Company Secretary and Compliance Officer. This resignation is effective from the close of business hours on February 10, 2026, and also applies to the company's wholly-owned subsidiary, Time Medical International Ventures (India) Private Limited. The board noted this change during their meeting on January 30, 2026. The departure is attributed to the individual seeking new career opportunities.

Mr. AravindKumar V to step down as Company Secretary and Compliance Officer on February 10, 2026
Resignation also covers the wholly-owned subsidiary, Time Medical International Ventures (India) Private Limited
Board of Directors approved the transition in a meeting held on January 30, 2026
Departure is cited as being for personal reasons and career growth opportunities

💡 This is a routine management change and does not impact the company's fundamental operations. Investors should look for the announcement of a qualified successor to ensure seamless regulatory compliance.

Fischer Medical Subsidiary Secures Rs 40 Crore Loan from HDFC Bank

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 30 Jan 2026, 05:11 PM

Fischer Medical Ventures' material subsidiary, Time Medical International Ventures (India) Private Limited, has entered into a secured loan agreement with HDFC Bank for Rs 40 Crores. The loan carries an interest rate of 3 months Repo plus 2.75% per annum. The facility is secured by a pledge of shares and Fixed Deposit collateral. This capital infusion will likely support the subsidiary's operational requirements or growth initiatives.

Loan amount of Rs 40 Crores sanctioned by HDFC Bank to the material subsidiary.
Interest rate set at 3 months Repo rate + 2.75% per annum.
Loan is secured through pledged shares and Fixed Deposit (FD) collateral.
Agreement approved by the Board of Directors on January 30, 2025.

💡 Investors should monitor the utilization of these funds and the subsequent impact on the subsidiary's revenue growth. The debt addition is manageable given the secured nature and competitive interest pricing.

Fischer Medical Q3 FY26 Consolidated Revenue Surges to ₹101 Cr; PAT at ₹19.2 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 04:49 PM

Fischer Medical Ventures reported a massive jump in consolidated revenue to ₹10,109.52 Lakhs for Q3 FY26, compared to ₹1,174.85 Lakhs in the same quarter last year. The company turned profitable on a consolidated basis with a PAT of ₹1,923.48 Lakhs, a significant recovery from a loss of ₹29.39 Lakhs in Q3 FY25. For the nine-month period, consolidated revenue reached ₹21,084.52 Lakhs, marking a substantial growth over the previous year's ₹6,152.45 Lakhs. However, the standalone business reported a loss of ₹166.93 Lakhs for the quarter, indicating that growth is heavily driven by its subsidiaries.

Consolidated revenue grew by approximately 760% YoY to ₹10,109.52 Lakhs in Q3 FY26.
Consolidated PAT turned positive at ₹1,923.48 Lakhs versus a loss of ₹29.39 Lakhs in the previous year's quarter.
Nine-month consolidated PAT stands at ₹3,813.89 Lakhs compared to a loss of ₹10.42 Lakhs in the prior period.
Board approved restructuring of Malaysian subsidiary Fischer Hospitality Sdn. Bhd. with a trustee holding 51%.
Company Secretary and Compliance Officer Mr. Aravindkumar V resigned effective February 10, 2026.

💡 The massive consolidated growth and turnaround to profitability are strong positive signals, though investors should note that the standalone entity remains in a loss. Monitor the appointment of the new Compliance Officer and the progress of the Malaysian subsidiary restructuring.

Fischer Medical Ventures Announces Internal Reorganization of Singapore Subsidiary

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 21 Jan 2026, 05:49 PM

Fischer Medical Ventures Limited has approved the transfer of its shareholding in PellucidCare Health Innovations Pte Ltd, a Singapore-based subsidiary, to another wholly owned subsidiary, FlynnCare Health Innovations Private Limited. This move is part of an internal group reorganization aimed at enhancing administrative and operational efficiency. The company has clarified that there will be no change in the ultimate ownership, control, or management of the foreign entity. As the transaction is between the holding company and its direct subsidiary, there is no material impact on the consolidated financial statements.

Transfer of PellucidCare Health Innovations Pte Ltd (Singapore) shares to FlynnCare Health Innovations Private Limited.
FlynnCare Health Innovations is a 100% wholly owned subsidiary of Fischer Medical Ventures.
Zero change in ultimate economic interest or control post-reorganization.
The transaction has no material impact on the consolidated financials of the company.
Move is intended solely for administrative and operational efficiency.

💡 This is a routine internal restructuring with no impact on the company's valuation or financial health. Investors should view this as a neutral administrative update.

Fischer Medical Ventures Reports 100% Investor Grievance Redressal for Q3 FY26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Jan 2026, 05:36 PM

Fischer Medical Ventures Limited has submitted its quarterly compliance report for the period ending December 31, 2025, as per SEBI Regulations. The report, issued by Adroit Corporate Services, shows that the company received only one investor grievance through the SCORES platform during the quarter. This single complaint was successfully resolved within the same period, resulting in zero pending complaints. The company maintained a clean record with no grievances regarding dividends, share transfers, or annual reports.

Total of 1 grievance received through the SEBI SCORES platform during the quarter ended December 31, 2025
100% resolution rate achieved with the single complaint disposed of during the same period
Zero pending complaints at both the beginning and the end of the quarter
No complaints reported regarding non-receipt of dividends, share certificates, or annual reports

💡 No action is required as this is a routine regulatory filing. The report confirms efficient investor grievance handling and standard corporate governance compliance.

Fischer Medical Ventures to Close Trading Window from Jan 1, 2025, for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 05:21 PM

Fischer Medical Ventures Limited has announced the closure of its trading window starting January 1, 2025, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of the company's unaudited financial results for the quarter ended December 31, 2025. The restriction applies to promoters, directors, and designated persons to prevent insider trading. The window will remain closed until 48 hours after the results are officially announced to the stock exchanges.

Trading window closure begins on Thursday, January 1, 2025.
Closure is related to the Unaudited Financial Results for the quarter ended December 31, 2025.
Restriction applies to all Promoters, Directors, and Designated persons of the company.
Window will reopen 48 hours after the financial results are declared.
Board meeting date for result approval to be announced separately.

💡 This is a routine regulatory filing and does not impact the company's fundamentals. Investors should monitor the upcoming board meeting date for the actual Q3 financial performance results.

Fischer Medical Shareholders Approve Appointment of Two Independent Directors

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 02 Dec 2025, 11:54 AM

Fischer Medical Ventures Limited has announced the successful appointment of Mr. Chan Sing En and Dr. Syed Jalaludin as Independent Directors following a postal ballot. The resolutions were passed with overwhelming majorities, with over 40.52 crore votes polled for each candidate. Mr. Chan Sing En received 99.99% approval, while Dr. Syed Jalaludin received 99.935% approval. These appointments are part of the company's ongoing efforts to strengthen its board and corporate governance.

Appointment of Mr. Chan Sing En as Independent Director approved with 99.99% votes in favor (40,52,76,391 votes).
Appointment of Dr. Syed Jalaludin as Independent Director approved with 99.935% votes in favor (40,52,74,450 votes).
A total of 40,52,77,402 votes were polled, representing approximately 62.49% of the total outstanding shares.
The remote e-voting period was conducted from October 31, 2025, to November 30, 2025.
The resolutions were passed as Special Business with the requisite majority as per SEBI regulations.

💡 Investors should view this as a routine strengthening of corporate governance. No immediate action is required, but shareholders may monitor how these new independent directors influence the company's strategic expansion in the medical sector.

Fischer Medical Ventures enters Indonesia for TB Eradication

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 01 Dec 2025, 09:50 AM

Fischer Medical Ventures Limited, through its subsidiary Time Medical International Ventures (India) Pvt Ltd, is entering Indonesia via a TB eradication partnership with the City of Jember. This collaboration involves PT Pariko and includes a pilot deployment of 250 AI-powered X-ray systems by March 2026. The order size is approximately USD 6.5 million, positioning FMV as a strategic partner in Indonesia’s public healthcare initiatives. This expansion could positively impact the company's revenue stream in the coming years.

Time Medical International Ventures (India) Pvt Ltd enters Indonesia
Pilot deployment of 250 units of AI-powered X-ray systems planned by March 2026
Order size is approximately USD 6.5 million
Partnership with the City of Jember for TB eradication

💡 Investors should monitor the progress of the pilot deployment and the potential for further expansion in Indonesia. Keep an eye on revenue growth related to this international venture.

View All FISCHER Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenues grew 120% YoY in H1 FY26 to INR 110 Cr. This was primarily driven by the Preventive Healthcare segment, which saw high adoption of wellness and mental health initiatives. The Radiology business sustained its performance levels from the previous fiscal year.

Geographic Revenue Split

The domestic Indian market remains the primary revenue contributor. Export sales accounted for approximately 5-10% of revenue in FY25, but the company is actively scaling this to capture higher margins in international markets.

Profitability Margins

Gross margins expanded to 30% (INR 35 Cr) in H1 FY26. PAT margins reached 16% (INR 19 Cr) in H1 FY26, a significant turnaround from the INR 0.2 Cr profit recorded in the same period the previous year.

EBITDA Margin

EBITDA margin stood at 25% (INR 30.5 Cr) for H1 FY26, representing a 22-fold increase YoY. This expansion is attributed to operating leverage following the FY24 reverse merger and cost-optimization strategies.

Capital Expenditure

In FY25, 100% of R&D investments were directed toward improving environmental and social impacts. While specific future INR Cr figures for expansion are not disclosed, the company is planning automation and capacity initiatives over the next 12-18 months.

Credit Rating & Borrowing

The company maintains a very low debt-to-equity ratio of 0.04 and holds a net cash position of INR 28 Cr, indicating minimal reliance on external borrowing and low interest sensitivity.

⚙️ Operational Drivers

Raw Materials

High-tech components for Radiology equipment, including energy-efficient magnets and air-cooled systems for MRI machines. Specific percentage of total cost per component is not disclosed.

Import Sources

Components are sourced globally to support the manufacturing facility located in the AP Medtech Zone, Visakhapatnam, India.

Key Suppliers

Time Medical is a key partner, providing exclusive technology and distribution rights for MRI systems in India and other regions.

Capacity Expansion

Manufacturing is established at the AP Medtech Zone in Visakhapatnam. Automation initiatives are planned for the next 12-18 months to enhance production efficiency, though specific unit capacity is not disclosed.

Raw Material Costs

Gross margins of 30% imply that raw material and direct production costs account for approximately 70% of revenue. The company uses a mix of outright sales and AMC/leasing models to manage cost recovery.

Manufacturing Efficiency

Profitability is driven by operating leverage, where fixed manufacturing costs are spread over a rapidly growing revenue base (120% growth).

📈 Strategic Growth

Expected Growth Rate

15-20%

Growth Strategy

The company aims to achieve a 50/50 revenue split between Imaging and Preventive Healthcare within 3 years. Strategy includes leveraging 'Make-in-India' for import replacement, expanding into mental health and wellness screening, and scaling export sales in MENA and SEA regions.

Products & Services

Time Medical MRI machines, Radiology equipment (CT scanners), FlynnCare connected healthcare solutions, mental health screening tools, and contactless health screening equipment.

Brand Portfolio

Fischer Medical Ventures, Time Medical (exclusive distribution), FlynnCare.

New Products/Services

New initiatives in mental health and wellness under the Preventive Healthcare segment, which was the primary driver for the 120% revenue growth in H1 FY26.

Market Expansion

Targeting growth in export markets, specifically leveraging distribution rights for MENA (Middle East and North Africa) and SEA (South East Asia).

Strategic Alliances

Exclusive distributorship and technology rights with Time Medical for MRIs and other Radiology equipment.

🌍 External Factors

Industry Trends

The Medtech sector is a 'sunrise sector' in India growing at 15-20%. Trends include a shift toward domestic manufacturing to replace imports and the rising adoption of contactless, AI-driven preventive screening.

Competitive Landscape

Competes with global medical imaging giants; positioned as a cost-effective domestic alternative under the 'Make-in-India' initiative.

Competitive Moat

Durable advantage through exclusive technology rights for Time Medical MRIs in specific regions and a manufacturing presence in the AP Medtech Zone, which provides regulatory and logistical benefits.

Macro Economic Sensitivity

Highly sensitive to Indian Medtech sector growth (15-20% CAGR) and government capital expenditure, which was allocated INR 11.1 Lakh Cr in the 2024-25 interim budget.

Consumer Behavior

Increasing consumer demand for preventive health, wellness, and mental health diagnostics following global health shifts.

Geopolitical Risks

Trade policies affecting the import of specialized medical components and the sustainability of 'Atmanirbhar Bharat' incentives.

⚖️ Regulatory & Governance

Industry Regulations

Subject to CDSCO standards and Medtech manufacturing norms in India; operations are influenced by Production Linked Incentive (PLI) schemes.

Environmental Compliance

Aligned with ISO 45001:2018; products designed with energy-efficient magnets and recyclable components to reduce environmental impact.

Taxation Policy Impact

Not disclosed; however, the company benefits from tax incentives related to the manufacturing sector and PLI schemes.

Legal Contingencies

No pending disciplinary actions, bribery, or corruption charges were reported for Directors or KMPs in the current financial year.

⚠️ Risk Analysis

Key Uncertainties

Dependence on government policy continuity for domestic manufacturing incentives and the 6-12 month long sales cycle for Radiology hardware which can lead to revenue volatility.